Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1809301
Original Article

Mutation Analysis of Advanced Non-Small Cell Lung Cancer: A Retrospective Observational Study from South India

Sanudev Sadanandan Vadakke Puthiyottil 
1   Department of Medical Oncology, Government Medical College, Kozhikode, Kerala, India
,
Arathi Edayattil
1   Department of Medical Oncology, Government Medical College, Kozhikode, Kerala, India
,
Mohamed Jabir
1   Department of Medical Oncology, Government Medical College, Kozhikode, Kerala, India
,
Jerin James 
2   Government Medical College, Kozhikode, Kerala, India
,
Supriya N. K.
3   Department of Pathology, Government Medical College, Kozhikode, Kerala, India
› Author Affiliations
Funding None.
› Further Information
Also available at
  Permissions and Reprints

Abstract

Introduction

Lung cancer is a leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) being the predominant type. Comprehensive genomic profiling plays a crucial role in identifying actionable mutations to guide personalized treatment strategies, especially in regions like India where late-stage diagnoses are common.

Objective

This retrospective observational study aimed to determine the prevalence of actionable mutations in patients with advanced NSCLC from a tertiary cancer care center in South India.

Materials and Methods

A retrospective observational study was conducted at the Department of Medical Oncology, Government Medical College, Kozhikode, South India. The study included 50 histologically confirmed patients with advanced NSCLC who underwent molecular testing between November 2022 and July 2024.

Results

Among the 50 patients, adenocarcinoma was the predominant histological subtype (70%), with TP53 and EGFR mutations found in 42 and 34%, respectively. Co-mutations, including TP53 + EGFR exon 19 deletions, were observed in 4% of cases. Low PD-L1 expression (<1%) was identified in 78% of patients, suggesting limited eligibility for single agent immunotherapy.

Conclusion

Comprehensive genomic profiling is largely inaccessible to most patients in India due to high costs, but targeted next-generation sequencing (NGS) panels offer a cost-effective way to optimize treatment. This study highlights the heterogeneity of mutations in NSCLC in South Indian patients and showcases the importance of targeted NGS panels in optimizing therapeutic strategies.

Keywords

non-small cell lung cancer - mutations - personalized treatment - immunotherapy - EGFR mutations

Patients' Consent

Written informed consents of patients were not taken as it is a retrospective observational study, and data were collected from hospital records.




Publication History

Article published online:
22 May 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bray F, Laversanne M, Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74 (03) 229-263
    CrossrefPubMedSearch in Google Scholar
  • 2 Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 2022; 40 (06) 611-625
    PubMedSearch in Google Scholar
  • 3 Mohan A, Garg A, Gupta A. et al. Clinical profile of lung cancer in North India: a 10-year analysis of 1862 patients from a tertiary care center. Lung India 2020; 37 (03) 190-197
    CrossrefPubMedSearch in Google Scholar
  • 4 Murali AN, Radhakrishnan V, Ganesan TS. et al. Outcomes in lung cancer: 9-year experience from a tertiary cancer center in India. J Glob Oncol 2017; 3 (05) 459-468
    CrossrefPubMedSearch in Google Scholar
  • 5 Biswas B, Talwar D, Meshram P. et al. Navigating patient journey in early diagnosis of lung cancer in India. Lung India 2023; 40 (01) 48-58
    PubMedSearch in Google Scholar
  • 6 Planchard D, Popat S, Kerr K. et al; ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl. 04) iv192-iv237
    CrossrefPubMedSearch in Google Scholar
  • 7 Ettinger DS, Wood DE, Aisner DL. et al. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw 2023; 21 (04) 340-350
    PubMedSearch in Google Scholar
  • 8 Prabhash K, Advani SH, Batra U. et al. Biomarkers in non-small cell lung cancers: Indian consensus guidelines for molecular testing. Adv Ther 2019; 36 (04) 766-785
    PubMedSearch in Google Scholar
  • 9 Munde S, Barodawala S, Lila K. et al. Molecular analysis for EGFR, ALK, and ROS1 alterations in over 3000 Indian patients with non-small-cell lung cancer: A retrospective observational study. Cancer Res Stat Treat 2024; 7: 11-18
    Search in Google Scholar
  • 10 Raman R, Ramamohan V, Rathore A, Jain D, Mohan A, Vashistha V. Prevalence of highly actionable mutations among Indian patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. Asia Pac J Clin Oncol 2023; 19 (01) 158-171
    PubMedSearch in Google Scholar
  • 11 Graham RP, Treece AL, Lindeman NI. et al. Worldwide frequency of commonly detected EGFR mutations. Arch Pathol Lab Med 2018; 142 (02) 163-167
    PubMedSearch in Google Scholar
  • 12 Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA 2019; 322 (08) 764-774
    CrossrefPubMedSearch in Google Scholar
  • 13 Normanno N, Barberis M, De Marinis F, Gridelli C. On The Behalf Of The Aiot Expert Panel. Molecular and genomic profiling of lung cancer in the era of precision medicine: a position paper from the Italian Association of Thoracic Oncology (AIOT). Cancers (Basel) 2020; 12 (06) 1627
    PubMedSearch in Google Scholar
  • 14 Mandal SK, Singh TT, Sharma TD, Amrithalingam V. Clinico-pathology of lung cancer in a regional cancer center in Northeastern India. Asian Pac J Cancer Prev 2013; 14 (12) 7277-7281
    PubMedSearch in Google Scholar
  • 15 Dey A, Biswas D, Saha SK, Kundu S, Kundu S, Sengupta A. Comparison study of clinicoradiological profile of primary lung cancer cases: an Eastern India experience. Indian J Cancer 2012; 49 (01) 89-95
    PubMedSearch in Google Scholar
  • 16 Baburao A, Narayanswamy H. Clinico-pathological profile and haematological abnormalities associated with lung cancer in Bangalore, India. Asian Pac J Cancer Prev 2015; 16 (18) 8235-8238
    PubMedSearch in Google Scholar
  • 17 Kaur H, Sehgal IS, Bal A. et al. Evolving epidemiology of lung cancer in India: reducing non-small cell lung cancer-not otherwise specified and quantifying tobacco smoke exposure are the key. Indian J Cancer 2017; 54 (01) 285-290
    CrossrefPubMedSearch in Google Scholar
  • 18 Lopes CDH, Antonacio FF, Moraes PMG. et al. The clinical and molecular profile of lung cancer patients harboring the TP53 R337H germline variant in a Brazilian Cancer Center: the possible mechanism of carcinogenesis. Int J Mol Sci 2023; 24 (20) 15035
    PubMedSearch in Google Scholar
  • 19 Canale M, Andrikou K, Priano I. et al. The Role of TP53 mutations in EGFR-mutated non-small-cell lung cancer: clinical significance and implications for therapy. Cancers (Basel) 2022; 14 (05) 1143
    PubMedSearch in Google Scholar
  • 20 Lai WA, Huang YS, Chang KC. et al. Next-generation sequencing in lung cancers-a single-center experience in Taiwan. Medicina (Kaunas) 2024; 60 (02) 236
    PubMedSearch in Google Scholar
  • 21 Kaler AK, Patel K, Patil H. et al. Mutational analysis of EGFR mutations in non-small cell lung carcinoma-an Indian perspective of 212 patients. Int J Environ Res Public Health 2022; 20 (01) 758
    PubMedSearch in Google Scholar
  • 22 Rajadurai P, Yap NY, Yousoof SBM, Cheah YK. Mutational profiling of lung cancer using Next generation sequencing: a Malaysian real-world clinical diagnostic experience. Journal of Molecular Pathology. 2023; 4: 31-43
    Search in Google Scholar
  • 23 Sharma R, Kamireddy AP, Hussaini SM, Chatterjee S, Hasan Q, Jain J. The landscape of actionable genomic alterations in lung adenocarcinomas in India. Front Genet 2023; 14: 1256756
    PubMedSearch in Google Scholar
  • 24 Roy M, Bal A, Gupta N, Prasad KT, Wakelee HA, Singh N. A brief report on the mutational landscape in non-small cell lung cancer of South Asian patients: comparison at a US and an Indian Institution. Lung India 2022; 39 (04) 315-318
    PubMedSearch in Google Scholar
  • 25 Xu Y, Tong X, Yan J, Wu X, Shao YW, Fan Y. Short-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms. Transl Oncol 2018; 11 (06) 1364-1369
    PubMedSearch in Google Scholar
  • 26 Zhang T, Wan B, Zhao Y. et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res 2019; 8 (03) 302-316
    PubMedSearch in Google Scholar
  • 27 Shang K, Huang H, Xu Y, Liu Y, Lu Z, Chen L. Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation. BMC Cancer 2022; 22 (01) 1295
    PubMedSearch in Google Scholar
  • 28 Zhang G, Tang X, Zhang X, Qiu X, Lai Q, Li J. Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced myocardial damage: a case report and literature review. Anticancer Drugs 2023; 34 (08) 954-961
    PubMedSearch in Google Scholar